GL CAPITAL
Established in 2010, GL Capital is a Greater China healthcare-focused, value-driven investment management group. Since inception, GL Capital has developed a reputation as the partner-of-choice for leading healthcare companies and demonstrated capability to add value to its portfolio companies.
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-06-08 | SciClone Pharmaceuticals | SciClone Pharmaceuticals acquired by GL Capital | 605 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-07 | ImmunOs Therapeutics | GL Capital investment in Series B - ImmunOs Therapeutics | 71 M CHF |
| 2022-06-07 | Nest | GL Capital investment in Series A - Nest | N/A |
| 2021-11-24 | Duoning Biotech | GL Capital investment in Series C - Duoning Biotech | N/A |
| 2021-11-10 | Hzymes Biotechnology | GL Capital investment in Series C - Hzymes Biotechnology | 800 M CNY |
| 2021-06-15 | Tongshu Gene | GL Capital investment in Series C - Tongshu Gene | 500 M CNY |
| 2021-01-14 | New Amsterdam Pharma | GL Capital investment in Series A - New Amsterdam Pharma | 160 M EUR |
| 2020-04-08 | Huayin Health | GL Capital investment in Series C - Huayin Health | 85 M USD |
| 2018-08-24 | Oxford Biodynamics | GL Capital investment in Post-IPO Equity - Oxford Biodynamics | 9.75 M GBP |
| 2011-02-24 | Pharmaron | GL Capital investment in Series C - Pharmaron | 40 M USD |